Key result
Maternal hyperhomocysteinaemia linked to ~190% higher risk of having a child with CHD.
Why the study?
Does maternal hyperhomocysteinaemia increase the risk of congenital heart disease in offspring?
Population
149 case-mothers and their children with congenital heart disease and 183 control-mothers with their children
Comparison
Maternal hyperhomocysteinaemia (>14.3 micromol/l) vs Maternal normohomocysteinaemia
Design
Case-control
Follow-up
Approximately 17 months after the index-pregnancy
Authors
Loading...
Should not yet alter preconception care; leaves open whether lowering homocysteine prevents congenital heart disease.
Case-Control (n=658)
No
Does maternal hyperhomocysteinaemia increase the risk of congenital heart disease in offspring?
Odds Ratio: 2.9 (95% CI 1.4–6)
p-value: p=0.004 for trend
Maternal hyperhomocysteinaemia is associated with a nearly 3-fold increased risk of congenital heart disease in offspring, partially linked to low folate and vitamin B12 status.
Verkleij‐Hagoort et al. (2006) conducted a case-control in Congenital heart disease (CHD) (n=658). Maternal hyperhomocysteinaemia (>14.3 micromol/l) vs. Normohomocysteinaemia was evaluated on Having a child with congenital heart disease (OR 2.9, 95% CI 1.4-6.0, p=0.004 for trend). Maternal hyperhomocysteinaemia (>14.3 micromol/l) was associated with a significantly increased risk of having a child with congenital heart disease (OR 2.9; 95% CI 1.4-6.0).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: